Protein A immunoadsorption cannot significantly remove the soluble receptor of urokinase from sera of patients with recurrent focal segmental glomerulosclerosis

Nephrology Dialysis Transplantation

Volumn 29, Issue 2, 2014, Pages 458-463

  Beaudreuil, Severine ^a,b   Zhang, Xiaomeng ^b   Kriaa, Faycal ^a   Dantal, Jacques ^c   Francois, Helene ^a,b   Vazquez, Aimé ^b   Charpentier, Bernard ^a,b   Lorenzo, Hans Kristian ^a,b   Durrbach, Antoine ^a,b  

^a IFRNT   (France)

^b INSERM U1014   (France)

^c ITUN Institut de Transplantation Urologie Nephrologie   (France)

Author keywords

focal and segmental glomerulosclerosis; immunoadsorption; protein A Sepharose column; soluble urokinase plasminogen activator receptor

Indexed keywords

CORTICOSTEROID; CREATININE; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PROTEIN A; SOLUBLE RECEPTOR OF UROKINASE; TACROLIMUS; UNCLASSIFIED DRUG; UROKINASE RECEPTOR;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG MEGADOSE; ELUTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FOCAL GLOMERULOSCLEROSIS; HUMAN; IMMUNOADSORPTION; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; PRIORITY JOURNAL; PROTEINURIA; RECURRENT DISEASE;

FOCAL AND SEGMENTAL GLOMERULOSCLEROSIS; IMMUNOADSORPTION; PROTEIN A SEPHAROSE COLUMN; SOLUBLE UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR;

ADULT; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; GRAFT REJECTION; HUMANS; IMMUNOSORBENT TECHNIQUES; KIDNEY TRANSPLANTATION; MALE; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; RECURRENCE; RETROSPECTIVE STUDIES; STAPHYLOCOCCAL PROTEIN A;

EID: 84896703215     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gft453     Document Type: Article

References (22)

1. Collins AJ, Foley RN, Chavers B et al. 'United States Renal Data System 2011 Annual Data Report: Atlas of chronic kidney disease and end-stage renal disease in the United States. Am J Kidney Dis 2012; 59: A7; e1-420
2. Schell C, Huber TB. New players in the pathogenesis of focal segmental glomerulosclerosis. Nephrol Dial Transplant 2012; 27: 3406-3412
3. Zenker M, Machuca E, Antignac C. Genetics of nephrotic syndrome: New insights into molecules acting at the glomerular filtration barrier. J Mol Med (Berl) 2009; 87: 849-857
4. Vinai M, Waber P, Seikaly MG. Recurrence of focal segmental glomerulosclerosis in renal allograft: An in-depth review. Pediatr Transplant 2010; 14: 314-325
5. Feld SM, Figueroa P, Savin V et al. Plasmapheresis in the treatment of steroid-resistant focal segmental glomerulosclerosis in native kidneys. Am J Kidney Dis 1998; 32: 230-237
6. Haas M, Godfrin Y, Oberbauer R et al. Plasma immunadsorption treatment in patients with primary focal and segmental glomerulosclerosis. Nephrol Dial Transplant 1998; 13: 2013-2016
7. Kemper MJ, Wei C, Reiser J. Transmission of glomerular permeability factor soluble urokinase plasminogen activator receptor (suPAR) from a mother to child. Am J Kidney Dis 2013; 61: 352
8. Rea R, Smith C, Sandhu K et al. Successful transplant of a kidney with focal segmental glomerulosclerosis. Nephrol Dial Transplant 2001; 16: 416-417
9. Canaud G, Zuber J, Sberro R et al. Intensive and prolonged treatment of focal and segmental glomerulosclerosis recurrence in adult kidney transplant recipients: A pilot study. Am J Transplant 2009; 9: 1081-1086
10. Zhang SY, Kamal M, Dahan K et al. c-mip impairs podocyte proximal signaling and induces heavy proteinuria. Sci Signal 2010; 3: Ra39
11. Dantal J, Bigot E, Bogers W et al. Effect of plasma protein adsorption on protein excretion in kidney-Transplant recipients with recurrent nephrotic syndrome. N Engl J Med 1994; 330: 7-14
12. Coppo R. Non-steroidal and non-cytotoxic therapies for nephrotic syndrome. Nephrol Dial Transplant 2008; 23: 1793-1796
13. Savin VJ, McCarthy ET, Sharma M. Permeability factors in focal segmental glomerulosclerosis. Semin Nephrol 2003; 23: 147-160
14. Wei C, El Hindi S, Li J et al. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med 2011; 17: 952-960
15. Smith HW, Marshall CJ. Regulation of cell signalling by uPAR. Nat Rev Mol Cell Biol 2010; 11: 23-36
16. Wei C, Moller CC, Altintas MMet al. Modification of kidney barrier function by the urokinase receptor. Nat Med 2008; 14: 55-63
17. Maas RJ, Wetzels JF, Deegens JK. Serum-soluble urokinase receptor concentration in primary FSGS. Kidney Int 2012; 81: 1043-1044
18. Sidenius N, Sier CF, Ullum H et al. Serum level of soluble urokinase-Type plasminogen activator receptor is a strong and independent predictor of survival in human immunodeficiency virus infection. Blood 2000; 96: 4091-4095
19. Sier CF, Stephens R, Bizik J et al. The level of urokinase-Type plasminogen activator receptor is increased in serum of ovarian cancer patients. Cancer Res 1998; 58: 1843-1849
20. McCarthy ET, Sharma M, Savin VJ. Circulating permeability factors in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2010; 5: 2115-2121
21. Blasi F, Carmeliet P. uPAR: A versatile signalling orchestrator. Nat Rev Mol Cell Biol 2002; 3: 932-943
22. Wei C, Trachtman H, Li J et al. Circulating suPAR in two cohorts of primary FSGS. J Am Soc Nephrol 2012; 23: 2051-2059